Any upward movement in predicted risk for subjects with MRSA implied improved reclassification, and any downward movement indicated worse reclassification.
However, these changes were not significant enough to have a significant improvement in risk reclassification indicated by net reclassification improvement.
In evidence to the home affairs committee last week before his dismissal, Nutt indicated that reclassification to class B might be in order.
When participants with and without the outcome are considered separately, any upward movement in disease categories for subjects with the outcome implies improved classification, and any downward movement indicates worse reclassification.
When inflammatory and metabolic biomarkers were added to the model, the IDI was 0.81 and the NRI was 0.63 (P < 0.0001), indicating strong reclassification improvement, whereas when GLDH was added to the model, the IDI was 0.24 and the NRI was 0.46 (P = 0.07), indicating moderate improvement.
When inflammatory and metabolic biomarkers were added to the model, the IDI was 0.43, and NRI >0) was 0.44 (P = 0.0004), indicating moderate reclassification improvement; when GLDH was added to the model, the IDI was 0.10 and the NRI >0) was 0.21 (P = 0.29), indicating weak improvement (Fig. 3).
However, the low magnitude of the effect and the modest improvement in discrimination and reclassification indicate that the GRS, in its present form, is insufficient to add valuable information in the clinical setting.
This finding could indicate efficient admission, slow reclassification process, or a mixture of both.
This finding could indicate efficient admission, slow reclassification process, or both.
The type of bead indicated is after reclassification.
